Sift Bio
Abstract Sift Bio brand background

Harnessing
Hidden Immunity.

Borrowing Nature’s Playbook To Fight Cancer and Autoimmunity

Using AI to decode nature’s signals to guide the next generation of immunotherapy development.

Sift is building a proprietary platform that combines AI, metagenomics, and high-throughput T-cell screening to discover molecules that drastically amplify immune responses, unlocking targeted, effective, and safe treatment for cancers and autoimmune diseases where current therapies fall short. Our ultimate goal is to bring durable disease control to every patient.

Diagram showing microorganisms training a naïve T-cell into a trained T-cell that targets disease cells

Our Science

Harnessing pre-existing antimicrobial memory to treat immune-dysregulated diseases.

Immune dysfunction underlies many of today’s most challenging diseases, from cancer to autoimmunity. At Sift, we address this challenge by pioneering a novel class of T-cell modulators derived from bacteria and viruses that frequently interact with our immune system. The SIFT™ Platform, our AI-driven discovery engine paired with high-throughput cellular screening, identifies microbially derived molecules that activate distinct subsets of pre-existing memory T cells and redirect them against disease targets of interest to restore immune balance and drive durable disease control.

Platform

Input
Disease targets
+ microbial genome data
SIFT™ Platform
AI discovery engine
+ high-throughput screening
Output
T-cell modulators
peptide · mRNA · DNA

Pipeline

Multiple therapeutic areas powered by the SIFT™ platform.

  • Oncology
    SIFT-1001

    SIFT™ molecules that activate memory T cells against hematological and solid tumors.

    Target Discovery & Validation
    Candidate Selection
    IND Enabling
    Early Clinical
    Late Clinical
    Partner
    Wholly owned
  • Autoimmunity
    SIFT-2001
    Partnered

    SIFT™ molecules are designed to recalibrate the balance between regulatory and effector T cells, restoring immune homeostasis.

    Target Discovery & Validation
    Candidate Selection
    IND Enabling
    Early Clinical
    Late Clinical
    Partner
    Top-10 Global Pharma

Team

A UC Berkeley spinout led by founders with deep experience in AI-driven discovery and translational immunology.

Meet the full team →

Key Investors

  • Freeflow Ventures logo
  • Lifespan Vision Ventures logo
  • Valuence Ventures logo
  • Eisai Innovation logo
  • SBI US Gateway Fund logo

Join Us

We’re hiring scientists, engineers, and operators who want to build a new class of immunotherapy from the ground up.

Interested in joining Sift? Get in touch →